Core Viewpoint - The company has entered into a memorandum of understanding with Watson Bio-Tech to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform, which includes joint development, clinical trials, registration, and sales and distribution [1][2] Group 1: Partnership Details - The memorandum outlines collaboration in establishing an RNA-centered research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology to advance RNA-based diagnostic products, vaccines, and therapeutics [1] - The partnership aims to accelerate clinical trials and regulatory approvals for existing and pipeline products in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve the ASEAN region and specific international markets for existing and pipeline products [1] - A supply chain will be established in Singapore to coordinate end production, quality, and commercial deployment of existing and pipeline products [1] Group 2: Strategic Value - The partnership is expected to generate significant strategic value, reinforcing the company's position as a pillar in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - It will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform will facilitate collaboration with global institutions to seize and expand regional opportunities [2] - The collaboration is anticipated to promote cross-border joint investment and cooperation opportunities, enhance corporate visibility, deepen R&D capabilities, and contribute to the long-term development and revenue diversification of the group [2]

Core Insights - The company has signed a memorandum of understanding with Yunnan Watson Bio-Technology Co., Ltd. to establish a strategic partnership focused on creating an RNA-centered prevention and precision medicine platform [1][2] - The memorandum outlines a two-year collaboration period and includes joint development, clinical trials, registration, and sales and distribution [1] Group 1 - The partnership aims to leverage complementary strengths to enhance the company's position in the growing RNA diagnostics and therapeutics ecosystem in the region [2] - The collaboration will expand the company's product portfolio in early detection and prevention solutions, accelerating revenue growth [2] - The RNA-centered platform is expected to facilitate cross-border investment opportunities, enhance corporate visibility, and deepen research and development capabilities [2] Group 2 - The partnership will establish an RNA-focused research center in Singapore, integrating proprietary disease RNA databases with Watson's mRNA technology [1] - Clinical trials and regulatory approvals for existing and pipeline products will be expedited in the ASEAN region [1] - A sales and distribution platform will be set up in Singapore to serve ASEAN and specific international markets [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） 自願性公告 與沃森的諒解備忘錄 本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 – 1 – 諒解備忘錄 進行諒解備忘錄項下合作的理由及裨益 本公司董事（「董事」）會（「董事會」）宣佈，本公司近期與雲南沃森生物技術股 份有限公司（「沃森」）訂立了一份諒解備忘錄（「諒解備忘錄」），據此，訂約方已 同意發揮各自的互補優勢，就創建以RNA為中心的預防及精準醫療平台建立戰 略合作夥伴關係，並涵蓋共同開發、臨床試驗及註冊以及銷售及分銷。諒解備 忘錄的期限自簽署日期（包括該日）起為期兩年。 有關沃森的資料 沃森成立於2001年，是中國領先的高科技生物製藥 ...